American Xeno

American Xeno, Inc. was a biotechnology company based in Boston, Massachusetts, dedicated to the advancement of xenotransplantation. The company focused on developing genetically engineered animals to provide a sustainable source of human-compatible organs, tissues, and cells, aiming to solve the global organ donor shortage. In 2008, American Xeno acquired the xenotransplantation-related intellectual property and assets of Infigen, Inc., a pioneer in animal cloning and transgenic technology. This acquisition included advanced nuclear transfer and genomic reprogramming technologies used to produce humanized proteins and tissues in mammals. The company's research targeted various medical needs, including organ failure, trauma, and chronic diseases. Although it was recognized as a significant player in the xenotransplantation field during the late 2000s, the company is no longer active.